vs
ALPHA PRO TECH LTD（APT）与AVANOS MEDICAL, INC.（AVNS）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是ALPHA PRO TECH LTD的13.0倍（$180.9M vs $13.9M）。ALPHA PRO TECH LTD净利率更高（5.0% vs -0.7%，领先5.8%）。AVANOS MEDICAL, INC.同比增速更快（0.7% vs 0.3%）。AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $51.0K）。过去两年AVANOS MEDICAL, INC.的营收复合增速更高（4.4% vs 1.4%）
Alpha Pro Tech Ltd是一家研发、生产和销售一次性防护服饰、口罩等个人防护用品及耐候屏障等建筑供应产品的企业，核心市场位于北美，主要服务医疗、工业、建筑领域的客户。
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
APT vs AVNS — 直观对比
营收规模更大
AVNS
是对方的13.0倍
$13.9M
营收增速更快
AVNS
高出0.4%
0.3%
净利率更高
APT
高出5.8%
-0.7%
自由现金流更多
AVNS
多$21.2M
$51.0K
两年增速更快
AVNS
近两年复合增速
1.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $13.9M | $180.9M |
| 净利润 | $698.0K | $-1.3M |
| 毛利率 | 37.1% | 47.5% |
| 营业利润率 | 6.9% | 1.4% |
| 净利率 | 5.0% | -0.7% |
| 营收同比 | 0.3% | 0.7% |
| 净利润同比 | -17.6% | 99.7% |
| 每股收益（稀释后） | $0.06 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APTAVNS
| Q4 25 | $13.9M | $180.9M | ||
| Q3 25 | $14.8M | $177.8M | ||
| Q2 25 | $16.7M | $175.0M | ||
| Q1 25 | $13.8M | $167.5M | ||
| Q4 24 | $13.8M | $179.6M | ||
| Q3 24 | $14.3M | $170.4M | ||
| Q2 24 | $16.3M | $171.7M | ||
| Q1 24 | $13.5M | $166.1M |
净利润APTAVNS
| Q4 25 | $698.0K | $-1.3M | ||
| Q3 25 | $976.0K | $-1.4M | ||
| Q2 25 | $1.2M | $-76.8M | ||
| Q1 25 | $613.0K | $6.6M | ||
| Q4 24 | $847.0K | $-397.3M | ||
| Q3 24 | $862.0K | $4.3M | ||
| Q2 24 | $1.6M | $1.8M | ||
| Q1 24 | $576.0K | $-900.0K |
毛利率APTAVNS
| Q4 25 | 37.1% | 47.5% | ||
| Q3 25 | 39.7% | 48.4% | ||
| Q2 25 | 36.8% | 52.6% | ||
| Q1 25 | 39.0% | 53.6% | ||
| Q4 24 | 37.6% | 54.6% | ||
| Q3 24 | 38.5% | 54.5% | ||
| Q2 24 | 42.0% | 55.7% | ||
| Q1 24 | 40.2% | 57.1% |
营业利润率APTAVNS
| Q4 25 | 6.9% | 1.4% | ||
| Q3 25 | 7.4% | 0.1% | ||
| Q2 25 | 8.0% | -42.6% | ||
| Q1 25 | 3.3% | 6.1% | ||
| Q4 24 | 4.9% | -233.0% | ||
| Q3 24 | 5.2% | 7.0% | ||
| Q2 24 | 10.5% | 3.7% | ||
| Q1 24 | 2.4% | 2.4% |
净利率APTAVNS
| Q4 25 | 5.0% | -0.7% | ||
| Q3 25 | 6.6% | -0.8% | ||
| Q2 25 | 7.5% | -43.9% | ||
| Q1 25 | 4.4% | 3.9% | ||
| Q4 24 | 6.1% | -221.2% | ||
| Q3 24 | 6.0% | 2.5% | ||
| Q2 24 | 10.1% | 1.0% | ||
| Q1 24 | 4.3% | -0.5% |
每股收益（稀释后）APTAVNS
| Q4 25 | $0.06 | $-0.02 | ||
| Q3 25 | $0.09 | $-0.03 | ||
| Q2 25 | $0.12 | $-1.66 | ||
| Q1 25 | $0.06 | $0.14 | ||
| Q4 24 | $0.07 | $-8.64 | ||
| Q3 24 | $0.08 | $0.09 | ||
| Q2 24 | $0.15 | $0.04 | ||
| Q1 24 | $0.05 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.0M | $89.8M |
| 总债务越低越好 | — | $90.3M |
| 股东权益账面价值 | $62.5M | $778.2M |
| 总资产 | $74.1M | $1.1B |
| 负债/权益比越低杠杆越低 | — | 0.12× |
8季度趋势，按日历期对齐
现金及短期投资APTAVNS
| Q4 25 | $17.0M | $89.8M | ||
| Q3 25 | $17.7M | $70.5M | ||
| Q2 25 | $14.5M | $90.3M | ||
| Q1 25 | $13.4M | $97.0M | ||
| Q4 24 | $18.6M | $107.7M | ||
| Q3 24 | $18.4M | $89.0M | ||
| Q2 24 | $16.2M | $92.2M | ||
| Q1 24 | $18.5M | $75.8M |
总债务APTAVNS
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $93.4M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | $125.3M | ||
| Q3 24 | — | $152.6M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $167.2M |
股东权益APTAVNS
| Q4 25 | $62.5M | $778.2M | ||
| Q3 25 | $62.5M | $778.0M | ||
| Q2 25 | $62.2M | $776.3M | ||
| Q1 25 | $61.7M | $839.4M | ||
| Q4 24 | $62.2M | $828.5M | ||
| Q3 24 | $62.1M | $1.2B | ||
| Q2 24 | $62.0M | $1.2B | ||
| Q1 24 | $61.6M | $1.2B |
总资产APTAVNS
| Q4 25 | $74.1M | $1.1B | ||
| Q3 25 | $73.9M | $1.1B | ||
| Q2 25 | $73.2M | $1.0B | ||
| Q1 25 | $72.2M | $1.1B | ||
| Q4 24 | $73.7M | $1.2B | ||
| Q3 24 | $73.3M | $1.7B | ||
| Q2 24 | $72.7M | $1.7B | ||
| Q1 24 | $72.7M | $1.7B |
负债/权益比APTAVNS
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $318.0K | $28.2M |
| 自由现金流经营现金流 - 资本支出 | $51.0K | $21.3M |
| 自由现金流率自由现金流/营收 | 0.4% | 11.8% |
| 资本支出强度资本支出/营收 | 1.9% | 3.8% |
| 现金转化率经营现金流/净利润 | 0.46× | — |
| 过去12个月自由现金流最近4个季度 | $1.7M | $43.1M |
8季度趋势，按日历期对齐
经营现金流APTAVNS
| Q4 25 | $318.0K | $28.2M | ||
| Q3 25 | $3.9M | $14.0M | ||
| Q2 25 | $2.1M | $6.8M | ||
| Q1 25 | $-4.0M | $25.7M | ||
| Q4 24 | $2.4M | $57.9M | ||
| Q3 24 | $5.3M | $23.0M | ||
| Q2 24 | $-873.0K | $27.8M | ||
| Q1 24 | $-1.2M | $-8.0M |
自由现金流APTAVNS
| Q4 25 | $51.0K | $21.3M | ||
| Q3 25 | $3.8M | $7.0M | ||
| Q2 25 | $1.9M | $-4.2M | ||
| Q1 25 | $-4.1M | $19.0M | ||
| Q4 24 | $970.0K | $53.1M | ||
| Q3 24 | $3.2M | $20.0M | ||
| Q2 24 | $-1.0M | $21.9M | ||
| Q1 24 | $-1.3M | $-12.1M |
自由现金流率APTAVNS
| Q4 25 | 0.4% | 11.8% | ||
| Q3 25 | 25.9% | 3.9% | ||
| Q2 25 | 11.7% | -2.4% | ||
| Q1 25 | -29.6% | 11.3% | ||
| Q4 24 | 7.0% | 29.6% | ||
| Q3 24 | 22.3% | 11.7% | ||
| Q2 24 | -6.2% | 12.8% | ||
| Q1 24 | -9.3% | -7.3% |
资本支出强度APTAVNS
| Q4 25 | 1.9% | 3.8% | ||
| Q3 25 | 0.7% | 3.9% | ||
| Q2 25 | 0.8% | 6.3% | ||
| Q1 25 | 1.0% | 4.0% | ||
| Q4 24 | 10.4% | 2.7% | ||
| Q3 24 | 15.1% | 1.8% | ||
| Q2 24 | 0.8% | 3.4% | ||
| Q1 24 | 0.6% | 2.5% |
现金转化率APTAVNS
| Q4 25 | 0.46× | — | ||
| Q3 25 | 4.02× | — | ||
| Q2 25 | 1.68× | — | ||
| Q1 25 | -6.46× | 3.89× | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 6.18× | 5.35× | ||
| Q2 24 | -0.53× | 15.44× | ||
| Q1 24 | -2.03× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APT
暂无分部数据
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
